Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 221-223

  Alvarado Esquivel, Cosme ^a   de la Ascensión Carrera Gracia, Manuela ^a   Conde González, Carlos Jesús ^b   Juárez Figueroa, Luis ^b   Ruiz Maya, Lilia ^c   Aguilar Benavides, Sergio ^c   Torres Valenzuela, Alejandro ^a   Sablon, Erwin ^d  

^a UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c Regional Laboratory of Epidemiologic Reference   (Mexico)

^d INNOGENETICS   (Belgium)

Author keywords

Drug resistance; Mutations; Viral infections

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIGEN DETECTION; ARTICLE; BIOASSAY; BLOOD SAMPLING; CHRONIC DISEASE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG USE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MEXICO; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEIN DOMAIN; VIRUS CARRIER; VIRUS ISOLATION; WILD TYPE;

CODON; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE AMPLIFICATION; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MEXICO; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 31544479584     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki457     Document Type: Article

References (31)

1. Falke D, Gerken G. Hepatitis B virus. In: Hahn H, Falke D, Kaufmann SHE, Ullmann U. Medizinische Mikrobiologie und Infektiologie. 5. Auflage. Berlin: Springer Medizin-Verlag, 2005; 640-9.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. Custer B, Sullivan SD, Hazlet TK et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 Suppl: S158-68.
4. Thomson EC, Main J. Advances in hepatitis B and C. Curr Opin Infect Dis 2004; 17: 449-59.
5. Brunetto MR, Bonino F. Treatment of chronic hepatitis B: From research to clinical practice via the consensus conferences. Curr Pharm Des 2004; 10: 2063-75.
6. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106.
7. Lagget M, Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2003; 4: 1821-7.
8. Fung SK, Lok AS. Treatment of chronic hepatitis B: Who to treat, what to use, and for how long? Clin Gastroenterol Hepatol 2004; 2: 839-48.
9. Lai CL, Yuen MF, Hui CK et al. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy. J Med Virol 2002; 67: 334-8.
10. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618-28.
11. Tang S, Ho SK, Moniri K et al. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 73: 148-51.
12. Manns MP, Neuhaus P, Atkinson GF et al. Famciclovir treatment of hepatitis B infection following, liver transplantation: A long-term, multicentre study. Transpl Infect Dis 2001; 3: 16-23.
13. Demirturk N, Usluer G, Ozgunes I et al. Comparison of different treatment combinations for chronic hepatitis B infection. J Chemother 2002; 14: 285-9.
14. Perrillo RP. Overview of treatment of hepatitis B: Key approaches and clinical challenges. Semin Liver Dis 2004; 24 Suppl 1: 23-9.
15. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
16. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-3.
17. Niesters HG, Honkoop P, Haagsma EB et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 1382-5.
18. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702-7.
19. Gunther S, von Breunig F, Santantonio T et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30: 749-54.
20. Pichoud C, Seigneres B, Wang Z et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230-7.
21. Leung N. Viral breakthrough during lamivudine therapy for chronic hepatitis B. Intervirology 2003; 46: 344-9.
22. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-33.
23. Leon P, Pozo F, Echevarria JM. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. Enferm Infecc Microbiol Clin 2004; 22: 133-7.
24. Thibault V, Aubron-Olivier C, Agut H et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16: 131-3.
25. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584-6.
26. Arauz-Ruiz P, Norder H, Robertson BH et al. Genotype H: A new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-73.
27. Thakur V, Sarin SK, Rehman S et al. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 2005; 24: 12-5.
28. Sun J, Wang Z, Ma S et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience. J Med Virol 2005; 75: 891-8.
29. Nogales MC, Serrano MC, Suarez E et al. Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations. Gastroenterol Hepatol 2004; 27: 515-20.
30. Aberle SW, Kletzmayr J, Watschinger B et al. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 1972-4.
31. Lok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-34.